Trial record 3 of 17 for:    "krabbe disease"

An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)

This study has been withdrawn prior to enrollment.
(Study halted prior to enrollment of first participant)
Sponsor:
Collaborators:
PharmaNet
Nextrials, Inc.
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT01093105
First received: March 24, 2010
Last updated: February 19, 2014
Last verified: February 2014
  Purpose

The objective of this study is to evaluate the natural history of disease progression in infants with globoid cell leukodystrophy (GLD).


Condition
Leukodystrophy, Globoid Cell

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multicenter, Prospective, Longitudinal, Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (Krabbe Disease)

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • To measure the change from baseline in growth parameters (eg, weight gain, linear growth, head circumference). [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To determine the onset date of inadequate oral nutrition, hydration, and/or ventilation as a biomarker for survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the change from baseline in clinical parameters of GLD disease progression from a standardized infant neurological examination and infant distress scales. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To assess the change from baseline in clinical parameters described in Hagberg's clinical staging. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To measure the time to absolute survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To assess the AE experience in this patient population [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 0
Detailed Description:

This study is being conducted to gather prospective data on disease progression in infants diagnosed with GLD. This study will be performed using protocol-defined, standardized assessments including clinical, developmental, and neurologic measures. All study visits will be conducted in the subject's home. No travel to the study site is necessary.

  Eligibility

Ages Eligible for Study:   up to 21 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects with a documented diagnosis of GLD and clinical signs and symptoms consistent with that diagnosis

Criteria

Inclusion Criteria:

Subjects must meet all of the following criteria to be considered eligible for this study:

  1. The subject has a documented diagnosis of GLD as evidenced by GALC enzyme activity or a GALC genotype that is predictive of GLD.
  2. The subject must have clinical signs and symptoms consistent with the diagnosis of infantile GLD including at least 2 of the following:

    1. Chronic difficulty with feeding or unexplained irritability or "fisting" or other signs of abnormal increased tone
    2. CT or MRI imaging, if performed during diagnostic evaluation prior to enrollment, consistent with GLD
    3. Failure to meet at least 2 age-specific developmental milestones consistent with GLD
    4. Loss of deep tendon reflexes or abnormal visual fixation or optic atrophy
  3. The subject has documented onset of signs and symptoms consistent with GLD at <12 months of age and is <21 months of age at time of study entry.
  4. The subject was born at a gestational age of 35-41 weeks.
  5. The subject had a birth weight of ≥2 kg.
  6. At study entry, the subject must be able to maintain oral nutrition and hydration without the use of supportive measures, defined as use of a feeding tube.
  7. At study entry, the subject must be able to maintain ventilation without the use of invasive supportive measures, defined as use of a breathing tube.
  8. The subject must be able, in the opinion of the Investigator, to accommodate the protocol requirements, including feasibility of study visits.
  9. The subject's parent(s) or legal guardian must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the subject's parent(s), or legal guardian.

Exclusion Criteria: Subjects who meet any of the following criteria are not eligible for this study:

  1. The subject has neurologic, hearing or vision impairment, difficulty swallowing or feeding, respiratory complications, behavioral disturbances, or other medical conditions that are not due to GLD and are likely to confound the scientific integrity or interpretation of study assessments, as determined by the Investigator.
  2. The subject has received treatment with any investigational drug or a device within the 30 days prior to study enrollment through study completion.
  3. The subject has received a cord blood or bone marrow transplant or is planning to receive one during the study.
  4. The subject's parent(s) or legal guardian is unable to understand the nature, scope, and possible consequences of the study, or does not agree to comply with the protocol defined schedule of assessments.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01093105

Sponsors and Collaborators
Shire
PharmaNet
Nextrials, Inc.
Investigators
Study Director: Lawrence Charnas, MD, PhD Shire Human Genetic Therapies, Inc.
  More Information

No publications provided

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01093105     History of Changes
Other Study ID Numbers: HGT-GLD-056
Study First Received: March 24, 2010
Last Updated: February 19, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Shire:
Leukodystrophy, Globoid Cell
Classic Globoid Cell Leukodystrophy
Early-Onset Globoid Cell Leukodystrophy
Globoid Cell Leukodystrophy
Globoid Cell Leukoencephalopathy
Infantile Globoid Cell Leukodystrophy
Late-Onset Globoid Cell Leukodystrophy
Leukodystrophy, Globoid Cell, Classic
Leukodystrophy, Globoid Cell, Early-Onset
Leukodystrophy, Globoid Cell, Infantile
Leukodystrophy, Globoid Cell, Late-Onset
Krabbe Disease
Krabbe Leukodystrophy
Krabbe's Disease
Krabbe's Leukodystrophy
Psychosine
galactosylsphingosine (psychosine) beta-galactosidase
Psychosine-UDP galactosyltransferase

Additional relevant MeSH terms:
Leukodystrophy, Globoid Cell
Hereditary Central Nervous System Demyelinating Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Leukoencephalopathies
Demyelinating Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on September 30, 2014